• +1-646-491-9876
    • +91-20-67278686

    Search

    Contact Dermatitis - Pipeline Review, H1 2017

    Contact Dermatitis - Pipeline Review, H1 2017

    • Report Code ID: RW0001767496
    • Category Pharmaceuticals
    • No. of Pages 56
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Contact Dermatitis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis - Pipeline Review, H1 2017, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape.

    Contact dermatitis is a type of skin inflammation that occurs when substances touching skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps, dry, cracked, red patches, which may resemble a burn and pain or tenderness. There are two types of contact dermatitis; irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Contact Dermatitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Contact Dermatitis (Dermatology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Contact Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 7 respectively.

    Contact Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Contact Dermatitis (Dermatology) .
    - The pipeline guide reviews pipeline therapeutics for Contact Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Contact Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Contact Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Contact Dermatitis (Dermatology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Contact Dermatitis (Dermatology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Contact Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Contact Dermatitis - Overview
    Contact Dermatitis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Contact Dermatitis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Contact Dermatitis - Companies Involved in Therapeutics Development
    Anacor Pharmaceuticals Inc
    AskAt Inc
    Brickell Biotech Inc
    Dr. August Wolff GmbH & Co KG Arzneimittle
    Edesa Biotech Inc
    Hapten Sciences Inc
    ILiAD Biotechnologies LLC
    Marinomed Biotechnologie GmbH
    Novartis AG
    Signum Dermalogix Inc
    Contact Dermatitis - Drug Profiles
    AAT-008 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AN-3485 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BBI-2000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    beta-escin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EB-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EB-05 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    grapiprant - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HPT-721 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pertussis [strain BPZE1] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    secukinumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SIG-1322 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    WOL-071007 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Contact Dermatitis - Dormant Projects
    Contact Dermatitis - Discontinued Products
    Contact Dermatitis - Product Development Milestones
    Featured News & Press Releases
    Nov 19, 2015: Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Contact Dermatitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Contact Dermatitis - Pipeline by Anacor Pharmaceuticals Inc, H1 2017
    Contact Dermatitis - Pipeline by AskAt Inc, H1 2017
    Contact Dermatitis - Pipeline by Brickell Biotech Inc, H1 2017
    Contact Dermatitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017
    Contact Dermatitis - Pipeline by Edesa Biotech Inc, H1 2017
    Contact Dermatitis - Pipeline by Hapten Sciences Inc, H1 2017
    Contact Dermatitis - Pipeline by ILiAD Biotechnologies LLC, H1 2017
    Contact Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2017
    Contact Dermatitis - Pipeline by Novartis AG, H1 2017
    Contact Dermatitis - Pipeline by Signum Dermalogix Inc, H1 2017
    Contact Dermatitis - Dormant Projects, H1 2017
    Contact Dermatitis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Contact Dermatitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Anacor Pharmaceuticals Inc
    AskAt Inc
    Brickell Biotech Inc
    Dr. August Wolff GmbH & Co KG Arzneimittle
    Edesa Biotech Inc
    Hapten Sciences Inc
    ILiAD Biotechnologies LLC
    Marinomed Biotechnologie GmbH
    Novartis AG
    Signum Dermalogix Inc

    Request for Sample

    Report Url http://www.reportsweb.com//contact-dermatitis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//contact-dermatitis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//contact-dermatitis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments